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Abstract
Background: Francisella tularensis subspecies tularensis is the causative agent of a spectrum of diseases collectively known
as tularemia. An attenuated live vaccine strain (LVS) has been shown to be efficacious in humans, but safety concerns have
prevented its licensure by the FDA. Recently, F. tularensis LVS has been produced under Current Good Manufacturing
Practice (CGMP guidelines). Little is known about the immunogenicity of this new vaccine preparation in comparison with
extensive studies conducted with laboratory passaged strains of LVS. Thus, the aim of the current work was to evaluate the
repertoire of antibodies produced in mouse strains vaccinated with the new LVS vaccine preparation.
Methodology/Principal Findings: In the current study, we used an immunoproteomics approach to examine the repertoire
of antibodies induced following successful immunization of BALB/c versus unsuccessful vaccination of C57BL/6 mice with
the new preparation of F. tularensis LVS. Successful vaccination of BALB/c mice elicited antibodies to nine identified proteins
that were not recognized by antisera from vaccinated but unprotected C57BL/6 mice. In addition, the CGMP formulation of
LVS stimulated a greater repertoire of antibodies following vaccination compared to vaccination with laboratory passaged
ATCC LVS strain. A total of 15 immunoreactive proteins were identified in both studies, however, 16 immunoreactive
proteins were uniquely reactive with sera from the new formulation of LVS.
Conclusions/Significance: This is the first report characterising the antibody based immune response of the new
formulation of LVS in the widely used murine model of tularemia. Using two mouse strains, we show that successfully
vaccinated mice can be distinguished from unsuccessfully vaccinated mice based upon the repertoire of antibodies
generated. This opens the door towards downselection of antigens for incorporation into tularemia subunit vaccines. In
addition, this work also highlights differences in the humoral immune response to vaccination with the commonly used
laboratory LVS strain and the new vaccine formulation of LVS.
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Introduction
The facultative intracellular bacterium, Francisella tularensis,i s
pathogenic for many mammalian species including humans,
causing a spectrum of diseases collectively called tularemia [1].
Clinically, F. tularensis subspecies holarctica strains (commonly called
type B strains) are responsible for the vast majority of human
infections followed by F. tularensis subspecies tularensis strains (type
A strains) [2]. Both subspecies are highly infectious, but only type
A strains are able to cause lethal infections in humans [2].
Mortality rates of up to 60% have been reported for untreated
human cases of disseminated infection caused by type A strains of
the pathogen [3]. In recent years, F. tularensis has gained significant
attention as one of six organisms designated as high priority agents
that could be exploited as agents of bioterror (category A
pathogens) by the US Center for Disease Control and Prevention.
Combined, the extreme infectivity and ease of dissemination of
type A F. tularensis have made it a threat to both military personnel
and civilians alike.
Currently, there is no licensed vaccine available in the USA to
protect against tularemia [4,5]. A live attenuated strain, designated
Live Vaccine Strain (LVS), was derived from a Soviet vaccine
strain in the 1960s and is used as an investigational new drug
(IND), primarily for the protection of laboratory workers and
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new vaccine candidates are judged. LVS also is the only tularemia
vaccine candidate to have been evaluated and shown to be
effective in humans. Consequently, there is recent renewed interest
in improving the manufacturing and testing of LVS. DynPort
Vaccine Company LLC, under contract to the Joint Vaccine
Acquisition Program (JVAP) has developed and improved the
manufacturing process for F. tularensis LVS in compliance with
Current Good Manufacturing Practice (CGMP) guidelines. This
new vaccine formulation (DVC lot 16 LVS) was the subject of a
recent toxicity study in the rabbit [6] and another clinical lot
(DVC Lot 17) manufactured using the same process was evaluated
in a recent Phase 1 clinical study in humans [7].
In order to license any tularemia vaccine, knowledge of the
mechanisms of protection or markers of vaccine ‘take’ will be
extremely useful. A series of human trials of LVS, conducted in the
1960s under the name ‘Operation Whitecoat’ demonstrated that
most human volunteers vaccinated with LVS were protected
against disease symptoms following systemic and aerosol challenge
with a virulent type A strain, SCHU S4 [4], and produced
agglutinating antibodies to undefined antigen preparations. The
identities of the corresponding immunoreactive proteins were not
determined, and antibody titers did not predict protection from
disease. Ethical considerations prevent a repeat of Operation
Whitecoat in the near future, and the natural incidence of
tularemia caused by type A F. tularensis is too low making it
impractical to carry out regular phase 3 clinical trials. Instead, any
tularemia vaccine, including LVS, will need to be evaluated for
efficacy using the FDA Animal Rule. This will necessitate the
development of animal models of tularemia to determine safety,
efficacy and correlates of protection.
Previous work has demonstrated that LVS vaccination can
protect some mouse strains (e.g., BALB/c, CH3/HeN), but not
others (e.g., C57BL/6, DBA) from systemic challenge with type A
strains [8–10]. Historically, studies in mice successfully vaccinated
with LVS have shown that protection against type A strains
appears to be mediated predominantly by CD4+ and CD8+ T
cells and the cytokine, gamma interferon, rather than by
antibodies [11–19]. It has been assumed that this is the case also
for humans, although more recent work suggests that a
combination of cell-mediated and humoral immunity are required
for protection [20]. It therefore remains possible that successful
vaccination also elicits antigen-specific antibody responses that
could potentially serve as independent correlates of protection or
markers of vaccine take. Such protein-based markers would be
well-adapted to high throughput screening assays that will be used
to determine the protection status of individuals post vaccination.
Recently, we and others have used an immunoproteomics
approach to determine the repertoire of immunoreactive proteins
generated in response to LVS vaccination of mice [21,22]. These
studies showed that mice generate multiple antibody specificities
following exposure to F. tularensis [21,22]. These studies used a
laboratory strain of LVS and no work has been carried out to
characterize the immunoproteomics profile of the new formula-
tion, lot 16 LVS. This current study builds upon our earlier
immunoproteomics work, using antisera from BALB/c and
C57BL/6 mice immunized with a new formulation of LVS.
Thus, the aim of the current work was to evaluate the repertoire of
antibodies produced in mouse strains vaccinated with lot 16 LVS.
Results
Previously, we have shown that F. tularensis LVS ATCC 29684
inoculated intradermally elicits a similar sub-lethal infection in
the skin, liver, and spleen of both BALB/c and C57BL/6 mice
that persists for approximately 2 weeks [8]. However, whereas
this infection renders BALB/c mice immune to a subsequent
systemic challenge with .100 LD50 of a virulent type A strain of
F. tularensis, it fails to protect C57BL/6 mice from a 100-fold
smaller challenge [8]. In an earlier study, we used an
immunoproteomics approach to determine whether protective
immunity correlated to a difference in specific antibody response
[23]. The current study builds upon this work, using antisera
from BALB/c and C57BL/6 mice immunized with a new
formulation of LVS (lot 16 LVS).
Our experimental strategy used 2D-Western blotting of total
soluble protein and membrane protein enriched fraction of LVS
lot 16, with proteins resolved across three partially overlapping pH
ranges. No immunoreactive proteins were observed with pI values
of less than 4 or greater than 7, therefore the data presented here
are limited to the separation range between pH 4–7. All sera were
used at appropriate dilutions, based on our previous work [23] and
no reactions with naı ¨ve control sera were observed. To examine
the Francisella-specific antibody response, all immunoblots were
performed in duplicate and representative blots are shown herein
(Figures 1 and 2).
Profile of immunoreactive proteins with antisera
generated by successful vaccination of BALB/c mice with
lot 16 LVS
Figure 1b shows 2D-Western blots of the lot 16 LVS total
soluble protein extract, separated between pH 4–7, probed with
antisera pooled from five lot 16 LVS vaccinated BALB/c mice.
Twenty-eight individual areas of immunoreactivity of varying
intensity were observed. All areas of immunoreactivity were
aligned to protein spots on equivalent silver stained 2D reference
gels (Figure 1b) and these protein spots were subsequently
identified using nano-LC MS/MS. In other cases, for example
FTT_0137, elongation factor Tu, was identified as a large
immunoreactive area, that corresponded to a ‘spot train’ on the
corresponding protein stained 2D gel (Figure 1a). In such cases
where all immunoreactive areas within a spot train were
identified as the same protein, a single arrow was used to
identify the protein in Figure 1a & b. The identified proteins are
summarized in Table 1 (specific details of peptide MS/MS scores
shown in Table S1) with a total of 18 unique proteins iden-
tified as reactive with sera from lot 16 LVS immunized BALB/c
mice. These areas of immunoreactivity and protein spots are
indicated in Figure 1. In some cases, the same immunoreactive
protein focused to more than one area on a gel, with protein
spots differing slightly in isoelectric point. For example, the
membrane protein FTT_0583 was observed to be immunoreac-
tive in two discrete protein spots, differing in both MW and pI
(Figure 1a & b).
2D-Western blots, using the membrane enriched lot 16 LVS
proteome as the antigen, were also probed with sera from lot 16
LVS immunized BALB/c mice. As shown in Figure 1d, this blot
showed 16 distinct areas of immunoreactivity. Subsequent protein
identification using mass spectrometry gave rise to 15 unique
proteins (Table 1). Eight of the immunoreactive proteins were only
detected in the membrane enriched proteome fraction (ATP
synthase beta chain (FTT0064), Intracellular growth locus subunit
B (FTT1358c), Hypothetical protein (FTT1441), NADH dehy-
drogenase I G subunit (FTT0037), OmpA Family Protein
(FTT0831c), Periplasmic solute binging protein (FTT0209c),
TypeIV pilin multimeric outer membrane protein (FTT1156c),
and hypothetical protein (FTT1778c)). By contrast, seven pro-
teins were identified in both membrane enriched and total
LVS Immunoproteomics
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(FTT1769c), Chitinase family 18 protein (FTT0715), Outer
membrane associated protein FopA (FTT0583), Chaperonin
GroEL (FTT1696), LemA-like protein (FTT0863c), Dihydroli-
poamide succunyl transferase component of 2-oxoglutarate
dehydrogenase complex (FTT0077), and Acontitate hydratase
(FTT0087).
When considering all the proteins immunoreactive with
immune sera from LVS vaccinated BALB/c mice, 15 had
previously been reported in the literature as immunoreactive with
either murine or human sera (indicated in Table 1) [21,23,24].
Eleven of the identified immunoreactive proteins have not, to our
knowledge, previously been documented to be immunoreactive
with Francisella antisera, including intracellular growth locus
subunit B (FTT1358c), ATPsynthase beta chain (FTT0064), type
IV pilin multimeric outer membrane protein (FTT1156c) and
NADH dehydrogenase G subunit (FTT0037).
Profile of immunoreactive proteins with antisera
generated by unsuccessful vaccination of C57BL/6 mice
with lot 16 LVS
2D-Western blots of lot 16 LVS total soluble proteome were
probed with pooled antisera from 5 LVS vaccinated C57BL/6
resulting in a total of 40 areas of immunoreactivity (Figure 2b).
Alignment of blots with equivalent protein stained 2D-PAGE gels
allowed identification of 20 unique proteins (Figure 2b & d and
Table 1, with specific details of peptide MS/MS scores shown in
Supplementary Table S1). This is in contrast to our previous
immunoproteomics study using antisera from C57BL/6 mice
vaccinated with a laboratory passaged strain of LVS, which
resulted in the identification of only four intensely reacting protein
spots within the LVS proteome [23].
Western blots of the lot 16 LVS membrane enriched proteome
showed 16 areas of immunoreactivity when probed with antisera
Figure 1. Two-dimensional immunoblots of Francisella tularensis LVS protein extracts probed with sera from BALB/c mice
successfully vaccinated with DVC-LVS Lot16. (a) Representative silver stained reference 2D-PAGE of LVS total protein lysates separated in pH
range 4–7 and b) equivalent immunoblot. (c) LVS membrane enriched fractions, separated in pH range 4–7 and (d) corresponding immunoblot.
Immunoreactive areas are labeled on Western blot images and the corresponding immunoreactive proteins are indicated on silver stained gels in (a)
and (c). The annotation numbers indicate the protein locus tag and are summarized in Table 1.
doi:10.1371/journal.pone.0010000.g001
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immunoreactivity was aligned with corresponding silver stained
protein gels and 15 unique proteins were identified (Table 1).
Certain proteins, such as the outer membrane protein, FopA and
the periplasmic solute binding protein were found to focus in
several distinct immunoreactive isoforms on 2D-PAGE, which
differed markedly in isoelectric point (Figure 2c). This may
represent genuine isoforms of the protein, and was consistently
observed on all protein stained 2D gels. The immunoreactivity of
each protein isoform, however, varied with the sera used to probe
the blot. Seven immunoreactive proteins were detected in both
total proteome and membrane enriched fractions, while eight were
uniquely identified in the membrane enriched fraction.
When considering the total 28 proteins that were immunore-
active with sera from C57BL/6 vaccinated mice, eleven of these
proteins were observed to be reactive only with sera from
immunized mice from this strain. The remaining 17 proteins
were also immunoreactive with sera from LVS vaccinated BALB/
mice. In contrast, 9 of the 28 proteins observed to be
immunoreactive with sera from BALB/c vaccinated mice were
not immunoreactive with sera from vaccinated C57BL/6 mice.
Functional classification of immunoreactive proteins and
potential diagnostic markers of vaccination
The immunoreactive proteins were classified according to their
computationally predicted features. These data are summarized
Figure 2. Two-dimensional immunoblots of Francisella tularensis LVS protein extracts hybridized with sera from C57BL/6 mice
unsuccessfully vaccinated with DVC-LVS Lot16. (a) Representative silver stained reference 2D-PAGE of LVS total protein lysates separated in pH
range 4–7 and b) equivalent immunoblot. (c) LVS membrane enriched fractions, separated in pH range 4–7 and (d) corresponding immunoblot.
Immunoreactive areas are labelled on Western blot images and the corresponding immunoreactive proteins are indicated on silver stained gels in (a)
and (c). The annotation numbers indicate the protein locus tag and are summarized in Table 1. Two spurious areas on blot (d) were observed and did
not correspond to areas of immunoreactivity.
doi:10.1371/journal.pone.0010000.g002
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LocusTag (a) Protein Name
Experimental
localization(b)
Observed Immunoreactivity
(this study)
(c) PSORT, COG
(d)
Previously
observed
(e)
BALB/c C57BL/6
Proteins immunoreactive with sera from successfully vaccinated mice only
FTT0064 ATP synthase beta chain M +++ Cytoplasmic,C
FTT0510 DNA gyrase subunit B TP +++ Cytoplasmic,L
FTT0511 Pyridoxine/pyridoxal 5-phosphate biosynthesis TP + Cytoplasmic, L
FTT0580 Hypothetical protein TP ++ Cytoplasmic, R
FTT0715 Chitinase family 18 protein TP, M +++ Unknown, G [22,23] M
FTT1358c Intracellular growth locus subunit B M + Unknown, S
FTT1373 3-oxoacyl-[acyl carrier protein] synthase III TP + Unknown, I
FTT1441 Hypothetical protein M ++ Cytoplasmic, P [24] H
FTT1530 Fusion product of 3-hydroxacyl-CoA TP +++ Cytoplasmic, I
Proteins immunoreactive with sera from successfully and unsuccessfully vaccinated mice
FTT0037 NADH dehydrogenase I G subunit M ++ + Unknown, C
FTT0062 ATP synthase alpha chain TP ++ /2 Unknown, C
FTT0077 Dihydrolipoamide succinyltransferase TP, M +++ ++ Cytoplasmic, C [23,24], MH
FTT0087 Aconitate hydratase TP, M ++ Cytoplasmic, C [24,24] H
FTT0137 Elongation factor Tu (EF-Tu) TP ++++ + Cytoplasmic, J [22,23] M
FTT0188 Cell division protein TP ++ Cytoplasmic, D [23,24] MH
FTT0472 Acetyl-CoA carboxylase biotin carboxyl carrier TP +/2 + Unknown, I [22,23] M
FTT0583 Outer membrane associated protein TP, M + *+ ++ OM, M [21–23] MH
FTT0721c Peroxidase/catalase TP + +++ OM, P [22–24] MH
FTT0831c OmpA family protein M ++ ++ Unknown, M [24] H
FTT0863c LemA-like protein TP M ++ + Cytoplasmic, S [23,24] MH
FTT0209c Periplasmic solute binding protein M ++ + Unknown, P
FTT1156c Type IV pilin multimeric outer membrane protein M ++ ++ OM, U
FTT1484c Pyruvate dehydrogenase E2 component TP ++ + Cytoplasmic, C [24] H
FTT1696 Chaperonin GroEL TP, M ++++ ++++ Cytoplasmic, O [22–24] MH
FTT1769c ClpB protein TP, M ++ Cytoplasmic, O [24] H
FTT1778c Hypothetical membrane protein M + +++ Unknown, - [23] M
Proteins immunoreactive with sera from unsuccessfully vaccinated mice only
FTT0183c 30S ribosomal protein S1 M ++ Cytoplasmic, J [23] M
FTT0189 UDP-3-O-[3-hydroxymyristoyl] TP + Unknown, M
FTT0323 Elongation factor G (EF-G) TP ++ Cytoplasmic, J [23] M
FTT0350 DNA-directed RNA polymerase alpha subunit TP ++ Cytoplasmic, K
FTT1060c 50S ribosomal protein L9 TP +/2 Cytoplasmic, J
FTT1103 Conserved hypothetical lipoprotein M + Unknown, O [23,24] MH
FTT1303c Hypothetical protein TP + Unknown, -
FTT1374 Malonyl coA-acyl carrier protein TP + Cytoplasmic, I
FTT1389 3-methyl-2-oxobutanoatehydroxymethyltransferase TP + Unknown, H
FTT1540c Hypothetical protein M ++ Unknown, R
FTT1269c Chaperone protein TP, M + Periplasmic, O [21–23] MH
(a)Locus tag from SCHU S4 database. This corresponds to numerically annotated immunoreactive areas in Figure 1.
(b)Indicates whether protein reactivity was observed in DVC LVS total soluble proteome extract (TP) or membrane enriched proteome (M).
(c)Indicates whether immunoreactivity was observed towards each protein was observed with immune sera from LVS vaccinated BALB/c or C57BL/6 mouse strains.
From–(no reactivity), (+/2) at the limits of detection, to ++++ (intense reactivity).
(d)PSORT–predicted subcellular location. COG- Clusters of Orthologous groups, functional annotation based upon protein sequence. OM indicates ‘outer membrane’.
(e)Number indicates reference in which protein immunoreactivity was previously reported. ‘M’ or ‘H’ indicate whether the reported study used sera drawn from murine
models of tularemia (M) or human subjects (H).
*Total intensity for all immunoreactive areas identified as FopA. Details of scoring for protein identification by using tandem mass spectrometry are shown in
supplementary table S1.
doi:10.1371/journal.pone.0010000.t001
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org/psortb/) predicts protein subcellular location for Gram
negative bacteria, based upon protein sequence. This was used
to predict the subcellular location of the immunoreactive proteins
identified in this work and showed cytoplasmic proteins to be
enriched, consisting of 50% of the total identified immunoreactive
proteins. Thirty-eight percent of the immunoreactive proteins
could not be predicted to localize to a specific subcellular location.
Twenty-nine percent of this subset of immunoreactive proteins
were hypothetical proteins. Overall, the antigenic proteins were
derived from diverse functional categories, including chaperonin
proteins, protein synthesis and carbohydrate metabolism. Both
chaperonins and proteins involved in aspects of energy metabolism
were highly represented among the immunoreactive proteins.
Stress response proteins have previously been reported to react
with convalescent sera in both tularemia and other diseases
[21,24–26]. The immunoreactive proteins included several
proteins that were observed to be increased in expression during
the later stages of murine tularemia (Acetyl CoA caboxylase,
Chitinase family 18 protein, Peroxidase/Catalase and hypothetical
protein FTT1303c) [27].
A total of nine proteins, combined from total protein and
membrane fraction, were observed only to be reactive with sera
from lot 16 LVS vaccinated BALB/c mice (ATP synthase beta
chain, DNA gyrase subunit B, Pyridoxine/pyridoxal 5-phosphate
biosynthesis protein, Hypothetical protein FTT0580, Intracellular
growth locus subunit B, 3-oxoacyl-[acyl carrier protein] synthase
III, Hypothetical protein FTT1441 and Fusion product of 3-
hydroxacyl-CoA Dehydrogenase and acyl-CoA-binding protein).
These nine proteins represent the first stage in the identification of
antibody-based markers of successful vaccination. By contrast, 11
of the protein spots were found to be immunoreactive to antisera
from both BALB/c and C57BL/6 vaccinated mouse strains
(Table 1). A further 11 proteins were reactive only with sera from
DVC LVS vaccinated C57BL/6 mice.
Discussion
There is a need for a safe and effective tularemia vaccine to
address potential bioterrorism threats. Historically, tularemia live
vaccines were successfully used in the former Soviet Union to
protect the general population against type B endemics, and in the
West to protect tularemia researchers against type A bacteria
[5,28,29]. In human volunteer studies conducted more than 40
years ago, most vaccinees immunized with F. tularensis LVS were
protected against subsequent pulmonary or systemic exposure to a
highly virulent typeA strainofthe pathogen [30–32].However, 10–
30% of vaccinees remained vulnerable to such challenge despite
seroconversion to undefined Francisella antigens [33]. No correlation
between the agglutinating antibody titre to these antigens and level
of protection against virulent F. tularensis was found [30,31,31–33].
Identification of correlates of protection will undoubtedly aid efforts
to license any potential tularemia vaccine. At present, LVS remains
the only vaccine candidate to show efficacy in humans. When
testing a vaccine in humanclinical trials isimpossible,the U.S. Food
and Drug Administration offers an alternative path to vaccine
licensure using the so-called ‘‘Animal Rule’’, whereby the efficacy of
such vaccines can be demonstrated through animal studies.
Application of the Animal Rule to current and future tularemia
vaccine candidates would be facilitated if an immunological
correlate of protection or marker of vaccine take in an animal
model was identified in order to bridge efficacy in animals to
immunogenicity in humans. The lot 16 LVS preparation was
produced under CGMP guidelines (described in [6]) and is
currently being characterized for safety in various animal models
and in humans [6,34]. For example, preliminary safety and
immunogenicity of the lot 16 LVS was conducted in rabbits [6],
but a concomitant challenge study was not performed. The murine
model of tularemia is well characterized in terms of pathogenesis
and immune response (reviewed in [35]) and represents an
accessible animal model for defining the immunogenicity of the
lot 16 LVS formulation. By comparing the repertoire of
immunoreactive proteins generated by successful and unsuccessful
vaccination of mice with LVS, we have gained insight into
immunoreactive proteins that may serve as markers of successful
vaccination. BALB/c mice, successfully vaccinated with lot 16 LVS,
generated antibodies towards nine proteins that were not
recognized by sera from unsuccessfully vaccinated C57BL/6 mice.
A comparison of the murine immunoreactive proteins identified
in our current work with those identified in our earlier study,
where mice were vaccinated with a laboratory strain of LVS,
shows some overlap and some noticeable differences. A total of 15
immunoreactive proteins were identified in both studies, indicating
commonalities in the immune response to LVS strains derived
from different sources. However, 16 immunoreactive proteins
identified in this study, were not identified in our previous work.
The most notable difference was observed in the immunopro-
teomic profiles of sera from LVS vaccinated C57BL/6 mice.
Previously, sera from C57BL/6 mice vaccinated with laboratory
LVS showed limited reactivity towards a small number of proteins.
By contrast, the newer lot of LVS preparation appeared to
stimulate a larger repertoire of antibodies in C57BL/6 mice even
though it still did not confer protection against subsequent
challenge. The reasons for the observed differences in antigenic
protein profiles remain unknown. Alternatively, the differences
may stem from the origins and preparations of the bacteria, such
as improvements in vaccine manufacture. Minor differences
between the laboratory passaged LVS and the newer LVS
preparation have been observed at the proteome level (unpub-
lished data) and it remains to be determined whether this has
contributed to the observed differences between the two studies.
The most challenging task in tularemia research, including the
development of correlates of protection, is demonstrating that the
findings in animal models are applicable to humans. Literature
reports of studies of the immunoproteome of LVS (ATCC29684)
with sera from tularemia patients have been added to a summary
of the data from the current study (Table 1). Little information
regarding the source of the human sera, the time after infection
and the protected status of the subjects are known. However, 13
proteins reported to be immunoreactive to human Francisella
antiserum [21,24] are also observed to be immunoreactive to
murine antisera in this current study. Of those proteins only two
were found exclusively to react with sera from successfully
vaccinated mice. These proteins were identified as OmpA and
hypothetical protein FTT1441. Whilst it is not feasible to
determine whether the immunoreactivity to these proteins is
indicative of the protected state of the human host, these proteins
represent leads in the search for protein based markers of vaccine
take for LVS vaccination. In this regard, immunoproteomics
studies of sera from other animal models of tularemia using
different host species, or human clinical trials will provide
additional information regarding antigens that are immunoreac-
tive across various species. It will then be possible to down-select to
commonly reactive protein antigens that can be incorporated into
an assay to rapidly screen sera for the presence of antibody
markers of successful vaccination. These data will also be useful in
down selecting to antigens that might be used in a protein based
subunit vaccine.
LVS Immunoproteomics
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Bacteria
The LVS strain used in murine immunizations was derived
directly from a vial of DVC lot 16 LVS (DVC Lot #703-0303-
016). This new formulation was derived from LVS NDBR101 lot
4, the history of which is briefly described elsewhere [6] and has
been produced using standardized fermentation, purification and
formulation processes. Working bacterial stocks were prepared as
described elsewhere [8,9].
Murine vaccine sera
Mouse challenge experiments were approved by and performed
at the National Research Council of Canada, Institute for
Biological Sciences in a federally-licensed small animal contain-
ment level 3 facility that is also approved by the NIH for Select
Agent research. Specific-pathogen-free female BALB/c mice were
purchased from Charles River Laboratories (St. Constant, Que.).
Mice were maintained and used in accordance with the
recommendations of the Canadian Council on Animal Care
Guide to the Care and Use of Experimental Animals. For
intradermal inoculations, stocks of the strains were diluted in
sterile saline. Actual concentrations of inocula were determined by
plating. Intradermal inocula (50 ml/mouse) were injected into a
fold of skin in the shaved mid-belly.
BALB/c (n=5) and C57BL/6 (n=5) mice were immunized
intradermally (ID) with ,5610
4 colony forming units of
reconstituted LVS lot 16. Mice were bled 28 days post-vaccination
and pooled sera were used to probe 2D Western blots of LVS
antigens. When these same mice were challenged intradermally 53
days post-vaccination with 1000 LD50 of the fully virulent SCHU
S4 strain, 5/5 C57BL/6 mice died between days 6–9, whereas 5/5
BALB/c mice survived to 20 days without any overt signs of
infection.
Two-dimensional polyacrylamide gel electrophoresis (2D
PAGE) and immunoblot analysis
Proteins were extracted either using a one-step extraction
procedure as described previously, to form total soluble protein
extracts [36]. Briefly, bacteria were grown in modified Mueller-
Hinton broth for 24–36 h at 37uC with shaking until bacterial
density reached 10
8–10
10 CFU/mL. Bacteria (LVS) were grown,
harvested and lysed within a BioSafety (BS) Level 2 containment
facility. Bacterial cultures were harvested in 1 mL aliquots by
centrifugation and the pellets were washed three times with sterile,
distilled water. Cell pellets were then resuspended in twelve times
the pellet volume of lysis solution (5 M urea, 2 M thiourea, 1%
DTT, 4% CHAPS, 0.5% ASB-14).
Crude membrane protein extracts were prepared as described
previously [36,37]. Bacterial cells were harvested from broth
culture to give a final pellet containing ,10
10 bacteria. The pellet
was washed twice with distilled water before resuspending in 4 mL
of 50 mM Tris/HCL, pH 7.3 with 0.7 mg DNase I (Sigma). The
cells were disrupted by sonication and unbroken cells removed by
centrifugation at 25006g for 10 min. The supernatant was diluted
to a final volume of 50 mL with ice-cold 0.1 M sodium carbonate,
pH 11 and the solution was gently stirred at 4uC for 1 h.
Carbonate treated membranes were collected by ultracentrifuga-
tion in a Beckman 55.2 Ti rotor at 100 0006g for 1 h at 4uC. The
supernatant was discarded and membrane pellet resuspended in
5 mL of ice cold 50 mM Tris/HCl to remove contaminants, and
then collected by centrifugation at 100 0006g for 30 min. This
wash procedure was repeated a second time, again discarding the
supernatant. The final membrane protein containing pellet was
solubilized for 2D electrophoresis in 1.0 mL of IEF solution (7 M
urea, 2 M thiourea, 1% (w/v) ASB-14, 4% (w/v) CHAPS, 1% (w/
v) DTT, and 0.5% (v/v) Biolytes 3–10 (Bio-Rad, Mississauga,
ON).
The extracted proteins were separated using immobilized pH
gradient strips (IPG), either linear pH 3–6, 4–7, 17 cm (Bio-Rad,
Mississauga, ON) or linear pH 6–11, 18 cm (GE Healthcare, Baie
d’Urfe, QC) essentially as described previously [23] using 100 mg
of protein/gel. Second dimension PAGE gels were run in
duplicate, with the first used for immunoblotting and the second
silver stained to serve as a 2D reference map for protein spot
identification.
Immunoblotting was carried out according to methods
previously published by others [38]. Proteins separated by 2D
PAGE were electroblotted onto PVDF membranes (Bio-Rad,
Mississauga, ON) at 15 V for 1 h using a semi-dry Trans Blot Cell
(Bio-Rad, Mississauga, ON). PDVF membranes were incubated
overnight in phosphate-buffered saline/Tween (PBST; (9 mM
sodium phosphate, 0.15 M NaCl, and 0.05% v/v Tween 20)
containing 5% w/v skim milk powder at 4uC with constant
rotation. Following two 5 min washes with PBST, the PVDF
membranes were re-incubated with mouse anti-Francisella serum;
anti-LVS sera were diluted 1:1000 in PBST containing 5% w/v
skim milk powder. Incubation was for 1 h at room temperature
with constant rotation. After washing with PBST, blots were then
incubated with peroxidase-conjugated goat anti-mouse immuno-
globulin (Perkin-Elmer Life and Analytical Sciences, Woodbridge,
Ontario). This was diluted 1:5000 in PBST containing 5% w/v
skim milk powder. Incubation was for 1 h at room temperature.
Reactive spots were visualized using the Western Lightning
Chemiluminescence kit (Perkin-Elmer Life and Analytical Scienc-
es, Woodbridge, Ontario) and images captured/transferred onto
BioMax Film (Perkin-Elmer Life and Analytical Sciences, Wood-
bridge, Ontario). Immunoblotting experiments were conducted in
duplicate, with no variation in results observed. Images of
immunoblots were captured using FluorS Scanner (Bio-Rad,
Mississauga, ON) and aligned with equivalent protein stained 2D
gels using PDQuest software (Bio-Rad, Mississauga, ON).
In-gel digestion and protein identification
Selected protein spots were excised and tryptically digested as
described previously [23]. Briefly, spots were excised manually
from silver stained 2D-PAGE and destained with 15 mM
potassium hexacyanoferrate, 50 mM sodium thiosulfate. Protein
spots were digested with 10 ng/uL trypsin in 50 mM ammonium
bicarbonate at 37uC for 16 hours. The resulting peptides were
analysed by nano-electrospray tandem mass spectrometry (nLC-
MS/MS). With a flow rate of 0.4 uL/min, peptides were eluted
from a 100 mm i.d. 6100 mm nanoAcquity UPLC 1.7 mmC 18
column (Waters, Mississauga, Ontario) with the following gradient:
1% B for 1 minute, 1%–45% B over 18 minutes, 45%–85% B
over 3 mninutes, 85%–1% B over 1 minute. The column was re-
equilibrated with 1% B for an additional 8 minutes. Solvent A is
0.1% formic acid in Optima LCMS water (Fisher Scientific
Canada, Whitby, Ontario). Solvent B is 0.1% formic acid in
acetonitrile. The peaklist files of MS
2 spectra of the excised protein
spots were searched against a database (2008.03.10) with 11947
entries consisting of the NCBI reference genomes for 7 strains of
Francisella (NCBI ids: NC_006570, NC_007880, NC_008245,
NC_008369, NC_008601, NC_009257, NC_009749) using the
MASCOT
TM search engine (version 2.2.03) (Matrix Science) for
protein identification. The mass tolerance used for precursor ions
was 60.8 Da and the mass tolerance for fragment ions was
60.15 Da. One missed cleavage site was permitted. The cut-off
LVS Immunoproteomics
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addition, all spectral matches were verified manually.
Supporting Information
Table S1 nLCMS/MS identification of immunoreactive pro-
teins from tryptic digests of protein gel spots.
Found at: doi:10.1371/journal.pone.0010000.s001 (0.09 MB
DOC)
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